Table 2.
Spread of nerve growth factor expression at the injection site
Patient | Anterior Site 1: Left | Anterior Site 1: Right | Intermediate Site 2: Left | Intermediate Site 2: Right | Posterior Site 3: Left | Posterior Site 3: Right | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | D/V | 1.48 ± 0.37 | D/V | 1.04 ± 0.21 | D/V | 1.30 ± 0.18 | D/V | 0.746 | D/V | 1.22 ± 0.14 | D/V | 0.813 ± 0.13 |
M/L | 1.59 ± 0.38 | M/L | 1.31 ± 0.15 | M/L | 1.27 ± 0.19 | M/L | 1.09 | M/L | 1.14 ± 0.19 | M/L | 0.467 ± 0.12 | |
2 | D/V | 0.576 ± 0.26 | D/V | 0.878 ± 0.021 | D/V | 0.432 ± 0.069 | D/V | 0.579 | D/V | 0.520 ± 0.024 | D/V | 0.696 |
M/L | 1.42 ± 0.054 | M/L | 0.460 ± 0.066 | M/L | 1.34 ± 0.30 | M/L | 0.372 | M/L | 0.520 ± 0.067 | M/L | 1.07 | |
3 | D/V | 0.527 ± 0.23 | D/V | 1.18 ± 0.31 | D/V | 1.73 ± 0.47 | ||||||
M/L | 0.794 ± 0.22 | M/L | 0.712 ± 0.12 | M/L | 1.44 ± 0.037 |
To quantify the diffusion of AAV2-NGF, the D/V and M/L spread of NGF expression (mm ± standard deviation) were measured and averaged among all sections with a detectable injection site. The mean spread of NGF expression around the injection site was 0.957 ± 0.34 mm, less than predicted by preclinical studies.
±, 1 standard deviation; AAV2, adeno-associated virus serotype 2; D/V, dorso/ventral; M/L, medio/lateral; NGF, nerve growth factor.